Measles and Rubella monitoring, June 2013
Measles and rubella are targeted for elimination in Europe by 2015. ECDC closely monitors progress towards interruption of endemic transmission of both diseases through enhanced surveillance and epidemic intelligence. Measles and rubella vaccinations are routinely delivered as trivalent measles-mumps-rubella (MMR) vaccine in Europe, and the first of the two recommended doses is normally given during the second year of life.
Brucellosis – Annual Epidemiological Report for 2017
19 Jun 2019 - In 2017, 381 confirmed brucellosis cases were reported in the EU/EEA. The notification rate in the EU/EEA was 0.09 cases per 100 000 population. The highest rates were reported in southern EU Member States (Greece, Italy and Portugal). The highest rate was observed in 25–44-year-old males (0.16 per 100 000). The notification rate was stable from 2013–2017 in the EU/EEA.
Diphtheria - Annual Epidemiological Report for 2017
19 Jun 2019 - For 2017, 39 cases of diphtheria due to toxigenic Corynebacterium diphtheriae or C. ulcerans were reported to ECDC. The highest proportion of C. ulcerans cases was among adults 45 years of age and above, whereas C. diphtheriae cases were more common in younger age groups. Among C. diphtheriae cases, 50% were reported as imported. High vaccination coverage is crucial to prevent diphtheria.
Congenital toxoplasmosis – Annual Epidemiological Report for 2016
19 Jun 2019 - In 2016, 242 confirmed cases of congenital toxoplasmosis were reported in the EU/EEA, with France accounting for 81% of all confirmed cases due to the active screening of pregnant women. The notification rate was 6.7 cases per 100 000 live births. No seasonal pattern was observed for the disease.